Translational lung cancer research · 2025
Short-course hypofractionated radiotherapy of 4 Gy per fraction for limited-stage small cell lung cancer: a randomized pilot trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xiao-Yang, Yan Bing, Zhang Jun-Qiang, Li Yan, Xia Da-Qing, Xie Wang, He Yuan, Wang Jian-Guo, Ma Jun, Cao Le-Jie, Qian Dong
Аннотация
BACKGROUND: Local-regional relapse remains high after the standard radiotherapy regimen for limited-stage small cell lung cancer (LS-SCLC). Short-course hypofractionated radiotherapy may improve disease control. In this single-institution open-label pilot trial, we aimed to explore the preliminary safety and efficacy of short-course hypofractionated radiotherapy with 4 Gy per fraction.
METHODS: LS-SCLC patients (18 to 75 years old) with Karnofsky performance scale score (KPS) over 70 were enrolled. Patients were randomized with a ratio of 1:1 to receive radiotherapy of 48 Gy/12 f once daily (low-dose arm) or 60 Gy/15 f once daily (high-dose arm). Concurrent chemotherapy was administered for 4 to 6 cycles. The primary objective was the radiation-induced toxicity and the secondary objective was 2-year survival outcome.
RESULTS: From August 2022 to August 2023, 44 patients with a median age of 63.5 years old were prospectively enrolled with 22 patients in each of the low-dose arm and the high-dose arm. The median follow-up time was 20 months (interquartile range, 15.3-28.0 months). The incidence of Grade 3 and higher toxicity was 13.6% in the low-dose arm and 36.4% in the high-dose arm (P=0.16), among which the predominant one was myelosuppression. The incidence of atelectasis (50.0% vs. 13.6%, P=0.02), cough (72.7% vs. 36.4%, P=0.03) and dyspnea (45.5% vs. 9.1%, P=0.02) was higher in the high-dose arm than the low-dose arm. The median overall survival was 30 months for all patients, not reached for the low-dose arm, and 30 months for the high-dose arm. The median progression-free survival was 23 months for all patients, 23 months for the low-dose arm, and 21 months for the high-dose arm, respectively. Only three patients developed local-regional relapse. Antitumor cytokines and cytotoxic CD8+ T cell population increased after radiotherapy.
CONCLUSIONS: Short-course hypofractionated radiotherapy of 4 Gy per fraction was preliminarily safe and efficient for LS-SCLC with high local-regional control. For striking the balance of toxicity and efficacy, the regimen of 48 Gy/12 f might be a novel and promising radiation regimen for future exploration.
TRIAL REGISTRATION: Hypofraction Radiotherapy for Limited-Stage Small Cell Lung Cancer: a randomized pilot trial (No. NCT05523908), registered on clinicaltrials.gov in August 2022.
METHODS: LS-SCLC patients (18 to 75 years old) with Karnofsky performance scale score (KPS) over 70 were enrolled. Patients were randomized with a ratio of 1:1 to receive radiotherapy of 48 Gy/12 f once daily (low-dose arm) or 60 Gy/15 f once daily (high-dose arm). Concurrent chemotherapy was administered for 4 to 6 cycles. The primary objective was the radiation-induced toxicity and the secondary objective was 2-year survival outcome.
RESULTS: From August 2022 to August 2023, 44 patients with a median age of 63.5 years old were prospectively enrolled with 22 patients in each of the low-dose arm and the high-dose arm. The median follow-up time was 20 months (interquartile range, 15.3-28.0 months). The incidence of Grade 3 and higher toxicity was 13.6% in the low-dose arm and 36.4% in the high-dose arm (P=0.16), among which the predominant one was myelosuppression. The incidence of atelectasis (50.0% vs. 13.6%, P=0.02), cough (72.7% vs. 36.4%, P=0.03) and dyspnea (45.5% vs. 9.1%, P=0.02) was higher in the high-dose arm than the low-dose arm. The median overall survival was 30 months for all patients, not reached for the low-dose arm, and 30 months for the high-dose arm. The median progression-free survival was 23 months for all patients, 23 months for the low-dose arm, and 21 months for the high-dose arm, respectively. Only three patients developed local-regional relapse. Antitumor cytokines and cytotoxic CD8+ T cell population increased after radiotherapy.
CONCLUSIONS: Short-course hypofractionated radiotherapy of 4 Gy per fraction was preliminarily safe and efficient for LS-SCLC with high local-regional control. For striking the balance of toxicity and efficacy, the regimen of 48 Gy/12 f might be a novel and promising radiation regimen for future exploration.
TRIAL REGISTRATION: Hypofraction Radiotherapy for Limited-Stage Small Cell Lung Cancer: a randomized pilot trial (No. NCT05523908), registered on clinicaltrials.gov in August 2022.